Major Ivermectin Study Omitted Hundreds of Participants, Researchers Say
By Zachary Stieber A large study examining ivermectin against COVID-19 included more participants than was reported in 2023, researchers acknowledged in a new correction. A U.S. government-funded trial arm examining ivermectin was said to have included 1,206 participants, including 602 who received ivermectin. The actual number of participants was 1,432, with 708 receiving ivermectin, Dr.
More Stories
Bonterra Resources Inc. (OTCMKTS:BONXF) Short Interest Down 50.8% in September
Bonterra Resources Inc. (OTCMKTS:BONXF – Get Free Report) saw a large decline in short interest during the month of September....
Short Interest in Bridges Capital Tactical ETF (NASDAQ:BDGS) Decreases By 50.0%
Bridges Capital Tactical ETF (NASDAQ:BDGS – Get Free Report) was the target of a significant decline in short interest in...
Premium Income 40 Barrier ETF (BATS:JULQ) Plans Dividend of $0.31
Premium Income 40 Barrier ETF (BATS:JULQ – Get Free Report) declared a dividend on Friday, September 27th, NASDAQ reports. Shareholders...
Vest 2 Year Interest Rate Hedge ETF (HYKE) To Go Ex-Dividend on September 30th
Vest 2 Year Interest Rate Hedge ETF (NYSEARCA:HYKE – Get Free Report) announced a dividend on Friday, September 27th, NASDAQ...
Cosan S.A. (NYSE:CSAN) Short Interest Update
Cosan S.A. (NYSE:CSAN – Get Free Report) saw a significant growth in short interest in September. As of September 15th,...
Quisitive Technology Solutions, Inc. (OTCMKTS:QUISF) Short Interest Update
Quisitive Technology Solutions, Inc. (OTCMKTS:QUISF – Get Free Report) saw a large decrease in short interest in September. As of...